Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06518564 · ClinicalTrials.gov registry record · Phase 2
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
A Phase 2 study of Endometrial Cancer and Recurrent Endometrial Carcinoma, sponsored by Panagiotis Konstantinopoulos, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06518564 is a Phase 2 study of Endometrial Cancer and Recurrent Endometrial Carcinoma that is actively recruiting participants, run by Panagiotis Konstantinopoulos, MD, PhD. The registered enrollment target is 25 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06518564, a Phase 2 study of Endometrial Cancer and Recurrent Endometrial Carcinoma, is actively recruiting participants, sponsored by Panagiotis Konstantinopoulos, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer. The names of the study drugs involved in this study are: * Avelumab (a type of human IgG1 antibody) * M1774 (a type of ATR inhibitor)
Conditions Studied
Interventions
- DRUG Avelumab
- DRUG M1774
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06518564
The ClinicalTrials.gov registry entry for NCT06518564 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Panagiotis Konstantinopoulos, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Avelumab is the first listed.
NCT06518564 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06518564 about?
NCT06518564 is a clinical study titled "Avelumab and M1774 in ARID1A-mutated Endometrial Cancer". The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer. The names of the study drugs involved in this study are: * Avelumab (a type of human IgG1 antibody) * M1774 (a type of ATR inhibitor)
What is the current status of trial NCT06518564?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-11-14. Estimated completion is 2029-08-31.
What conditions does trial NCT06518564 study?
This clinical trial studies the following conditions: Endometrial Cancer, Recurrent Endometrial Carcinoma, ARID1A Gene Mutation.
What interventions are being tested in trial NCT06518564?
The interventions under investigation include: Avelumab (DRUG), M1774 (DRUG).
Who is sponsoring clinical trial NCT06518564?
This trial is sponsored by Panagiotis Konstantinopoulos, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06518564 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.